Who are High-titer anti-influenza plasma's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): CCP, COVID19 convalescent plasma infusion, Low-titer anti-influenza plasma.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/high-titer-anti-influenza-plasma.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

High-titer anti-influenza plasma — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High-titer anti-influenza plasma (High-titer anti-influenza plasma) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Convalescent plasma. Area: Infectious Disease / Virology.

phase 3 Convalescent plasma Influenza virus surface antigens (hemagglutinin, neuraminidase) Infectious Disease / Virology Biologic Live · refreshed every 30 min

Target snapshot

High-titer anti-influenza plasma (High-titer anti-influenza plasma) — National Institute of Allergy and Infectious Diseases (NIAID). High-titer anti-influenza plasma provides passive immunotherapy by transferring high levels of neutralizing antibodies from recovered influenza patients to treat active influenza infection.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
High-titer anti-influenza plasma TARGET	High-titer anti-influenza plasma	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	Convalescent plasma	Influenza virus surface antigens (hemagglutinin, neuraminidase)
CCP	CCP	Metro Infectious Disease Consultants	marketed	Convalescent plasma	SARS-CoV-2 spike protein and other viral antigens
COVID19 convalescent plasma infusion	COVID19 convalescent plasma infusion	Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno	phase 3	Passive immunotherapy / Convalescent plasma
Low-titer anti-influenza plasma	Low-titer anti-influenza plasma	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	Convalescent plasma	Influenza virus surface antigens (hemagglutinin, neuraminidase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Convalescent plasma class)

National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
Metro Infectious Disease Consultants · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). High-titer anti-influenza plasma — Competitive Intelligence Brief. https://druglandscape.com/ci/high-titer-anti-influenza-plasma. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab